创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels Biotechnology: Advantages of Humanized Models of the Immune System

  • Categories:Company news
  • Author:InnoModels Biotechnology
  • Origin:InnoModels Biotechnology
  • Time of issue:2024-01-24 16:32
  • Views:

(Summary description)InnoModels's Humanized Model of the Immune System is a remarkable biomedical research technology with many advantages that provide scientists with a powerful tool to advance research in the field of immunology.

InnoModels Biotechnology: Advantages of Humanized Models of the Immune System

(Summary description)InnoModels's Humanized Model of the Immune System is a remarkable biomedical research technology with many advantages that provide scientists with a powerful tool to advance research in the field of immunology.

  • Categories:Company news
  • Author:InnoModels Biotechnology
  • Origin:InnoModels Biotechnology
  • Time of issue:2024-01-24 16:32
  • Views:
Information

InnoModels's Humanized Model of the Immune System is a remarkable biomedical research technology with many advantages that provide scientists with a powerful tool to advance research in the field of immunology. The following are some of the significant advantages of the model:
1. Humanized realism: The model creates a highly realistic humanized environment by integrating multiple key cell types and factors of the human immune system. This allows researchers to more realistically simulate the complexity of the human immune system, providing a more reliable basis for experiments.
2. Multi-field research applications: The humanized model of the immune system is widely used in many research fields such as immunotherapy, cancer research, infectious diseases, autoimmune diseases, and so on. Its comprehensiveness and flexibility enable researchers to conduct diverse experiments and studies in different fields.

 


3. Accurate drug screening and evaluation: The model provides an accurate and efficient platform for drug screening. Researchers can evaluate the effects of potential therapeutic drugs in a simulated immune system environment, accelerating the process of new drug development and reducing the risk of clinical trials.
4. Personalized Service: InnoModels Biotechnology provides personalized service by offering different types and configurations of humanized models of the immune system according to the specific needs of researchers. This customized service enables researchers to obtain the most suitable research tools according to the uniqueness and complexity of their experimental design.
5. In-depth study of immune system mechanisms: The model provides a unique opportunity for in-depth study of immune system mechanisms. With controlled experimental conditions, researchers can adjust cellular composition and environmental parameters to delve deeper into the function of the immune system in various physiological and pathological states.
6. Sustainable Supply Chain: Through efficient supply chain management, InnoModels Biotechnology ensures that customers can obtain the required humanized models of the immune system in a timely manner, without any interruption in supply, thus guaranteeing the smooth progress of their research projects.
By combining realism, flexibility and accuracy, the humanized models of the immune system from InnoModels Biotechnology provide researchers with an unprecedented research tool that contributes to scientific discovery and innovation in the field of immunology. The widespread application of this technology is expected to lay a solid foundation for the discovery and development of future therapies.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司